Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

[摘要]

[学科分类] 肿瘤学

[关键词] Metastatic colorectal cancer;Randomized phase III clinical trial;XELIRI;Bevacizumab;Second-line therapy